In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Immediate and long-term outcomes after endovascular treatment of left main coronary artery bifurcation stenosis

Session Poster Session 6

Speaker Associate Professor Daniil Maximkin

Congress : ESC Congress 2013

  • Topic : interventional cardiology and cardiovascular surgery
  • Sub-topic : Coronary Intervention: Outcome
  • Session type : Poster Session
  • FP Number : P4823

Authors : D Maximkin (Moscow,RU), Z Shugushev (Moscow,RU)

Authors:
D. Maximkin1 , Z. Shugushev1 , 1Peoples Friendship University of Russia (RPFU) - Moscow - Russian Federation ,

Citation:
European Heart Journal ( 2013 ) 34 ( Abstract Supplement ), 875-876

Objective: To estimate the immediate and long-term outcomes after endovascular treatment in patients with Left Main Coronary Artery (LMCA) bifurcation lesions.

Methods: 94 patients were enrolled and randomized in 2 groups. In group I (n = 51) the strategy called "one stent" ("provisional T" technique) was chosen. Patients of group II (n = 43) underwent "two stent" strategy. Final kissing carried out in all patients. Inclusion criteria: presence of true bifurcation lesions of the LMCA (by A. Medina); III-IV functional class of angina; positive stress tests. Indications for endovascular treatment were identified during consultation which was attended by cardiologists, heart surgeons and endovascular surgeons ("heart team"). Only drug eluting stents were used.

Results: Technical success of stenting achieved in all patients of group II (100%) and in 88.3% patients of group I (p>0.05). Hospital survival in both groups was 100%, during hospital stay no MACE cases were observed in both groups. In 6 cases (11.7%) "provisional-T" stenting became unsuccessful due to developing myocardial ischemia and negative ischemic ECG dynamics, thus technique was switched to "two stent" strategy. In all cases "revers culotte" stenting technique was performed. Risk factors of switching from "one stent" to "two stent" technique were identified, the most significant might be considered as: angle of circumflex artery less than 70 degree; length of the circumflex artery lesion more than 5 mm; calcification of the both branches. Long-term outcomes data were gained from 70 patients (36 of group I and 34 of group II). Follow-up duration was 1.5-3 years (avg. 25±1.6 months). Survival in both groups was 100%. Nonfatal myocardial infarction developed in 2 patients of group I (5.5%) and in 1 patient of group II (2.9%) (p > 0.05). Circumflex artery restenosis developed in 25% patients of group I and in 5.8% patients of group II (p<0.001). Frequency of Target Lesion Revascularization (TLR) was 2.9% in group II and 13.8% in group I (p<0.05). Definite late stent thrombosis occurred in 2.7% patients of group I and in 2.9% patients of group II (p>0.05). Patients of group II showed a significant increase in global myocardial contractility, compared to patients undergone "one stent" strategy stenting (59.1±4.44% and 57.34±4.91% resp., p<0.05).

Conclusion: In patients with true LMCA bifurcation stenosis the strategy of "two stents" might be considered as preferable due to significant lower prevalence of in-stent restenosis and TLR, as well as to significant increase in global myocardial contractility.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are